PDF DatasheetHuman Anti-Anti-CDAnti-CD95L Antibody Product Attributes
Anti-CDAnti-CD95L Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:
Variations in Fas Ligand / CD178 / CD95L antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. Low, but measureable presence of Fas Ligand / CD178 / CD95L could be seen in cells in the seminiferous ducts in testis, cells in the tubules in kidney, exocrine glandular cells in the pancreas, glandular cells in the appendix, duodenum, epididymis, fallopian tube, small intestine, stomach and thyroid gland, islets of Langerhans in pancreas, lymphoid tissue in appendix, neuronal cells in the caudate nucleus, cerebral cortex and hippocampus, non-germinal center cells in the lymph node and tonsil, Purkinje cells in the cerebellum and squamous epithelial cells in the tonsil. We were unable to detect Fas Ligand / CD178 / CD95L in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of FasL / CD178 / CD95L expression as measured by anti-FasL / CD178 / CD95L antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | + | – | – | – | – | – | – | – | – | – | – | – | – | – | + | – |
| FASLG Variability | + | ++ | + | + | ++ | + | ++ | ++ | + | + | + | + | ++ | + | + | + | + | ++ | ++ | + |
| Anti-CDAnti-CD95L General Information | |
|---|---|
| Alternate Names | |
| Fas Ligand, FASLG, CD95L, TNFSF6, APT1LG1, TNLG1A, CD95-L, ALPS1B, FASL, CD95L, APTL, CD178 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | FASLG |
| Entrez Gene ID | 356 |
| Ensemble Gene ID | ENSG00000117560 |
| RefSeq Protein Accession(s) | NP_000630, NP_001289675 |
| RefSeq mRNA Accession(s) | NM_001302746, NM_000639 |
| RefSeq Genomic Accession(s) | NC_018912, NG_007269, NC_000001 |
| UniProt ID(s) | P48023, Q53ZZ1 |
| UniGene ID(s) | P48023, Q53ZZ1 |
| HGNC ID(s) | 11936 |
| Cosmic ID(s) | FASLG |
| KEGG Gene ID(s) | hsa:356 |
| PharmGKB ID(s) | PA56 |
| General Description of Anti-CDAnti-CD95L. | |
| The NOK-1 antibody reacts with human CD178 (Fas ligand) in both membrane bound and soluble forms. Fas ligand is a 40 kDa transmembrane glycoprotein, a member of the TNF family, and is expressed by activated T and NK cells, neutrophils, and monocytes. Interactions between CD178 (Fas ligand) and CD95 (Fas) induce a program of apoptosis and play a key role in immune regulation and homeostasis. The extracellular domain of human CD178 can be cleaved from the surface by matrix metalloproteinases (MMPs) resulting in a 26 kDa soluble protein. | |
There are no reviews yet.